î
îŒ
î
Zymeworks Inc
ZYME26.860USD
+0.070+0.26%
çµå€Â 12/24, 13:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
2.03Bæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± Zymeworks Inc äŒæ¥å
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Companyâs Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Zymeworks Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãZYME
äŒç€ŸåZymeworks Inc
äžå Žæ¥Jun 24, 2019
æé«çµå¶è²¬ä»»è
ãCEOãGalbraith (Kenneth H)
åŸæ¥å¡æ°280
蚌åžçš®é¡Ordinary Share
決ç®ææ«Jun 24
æ¬ç€Ÿæåšå°108 Patriot Drive, Suite A
éœåžMIDDLETOWN
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·19709
é»è©±çªå·13022748744
ãŠã§ããµã€ãhttps://www.zymeworks.com/
äŒæ¥ã³ãŒãZYME
äžå Žæ¥Jun 24, 2019
æé«çµå¶è²¬ä»»è
ãCEOãGalbraith (Kenneth H)
Zymeworks Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Oleg Nodelman
Mr. Oleg Nodelman
Independent Director
Independent Director
--
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Acting Chief Investment Officer
Acting Chief Investment Officer
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Sun, Nov 16
æŽæ°æå»: Sun, Nov 16
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
EcoR1 Capital, LLC
30.69%
Rubric Capital Management LP
6.29%
BVF Partners L.P.
5.26%
Morgan Stanley & Co. LLC
5.23%
Redmile Group, LLC
4.95%
ä»ã®
47.56%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
EcoR1 Capital, LLC
30.69%
Rubric Capital Management LP
6.29%
BVF Partners L.P.
5.26%
Morgan Stanley & Co. LLC
5.23%
Redmile Group, LLC
4.95%
ä»ã®
47.56%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor/Hedge Fund
51.37%
Investment Advisor
19.68%
Hedge Fund
18.70%
Research Firm
6.53%
Private Equity
2.79%
Individual Investor
0.88%
Pension Fund
0.31%
Venture Capital
0.28%
Sovereign Wealth Fund
0.27%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
390
74.41M
99.43%
-2.56M
2025Q2
383
76.90M
102.73%
+2.83M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
2023Q3
376
69.54M
103.06%
-33.91M
2023Q2
364
70.30M
109.70%
-27.74M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
EcoR1 Capital, LLC
22.97M
30.56%
+5.09M
+28.44%
Jun 30, 2025
Rubric Capital Management LP
4.71M
6.27%
+372.11K
+8.58%
Jun 30, 2025
BVF Partners L.P.
4.31M
5.73%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
3.62M
4.82%
+317.19K
+9.60%
Jun 30, 2025
Redmile Group, LLC
4.15M
5.52%
-638.32K
-13.33%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
4.14%
-287.50K
-8.46%
Jun 30, 2025
The Vanguard Group, Inc.
2.46M
3.27%
+694.76K
+39.45%
Jun 30, 2025
Perceptive Advisors LLC
1.28M
1.7%
-589.40K
-31.61%
Jun 30, 2025
Vestal Point Capital, LP
1.15M
1.53%
+650.00K
+130.00%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
1.66M
2.2%
+274.20K
+19.83%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
Tema Oncology ETF
2.25%
Virtus LifeSci Biotech Clinical Trials ETF
0.99%
ProShares Ultra Nasdaq Biotechnology
0.24%
iShares Micro-Cap ETF
0.18%
Federated Hermes MDT Small Cap Core ETF
0.15%
WisdomTree US SmallCap Quality Growth Fund
0.15%
SPDR S&P International Small Cap ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.12%
詳现ãèŠã
Tema Oncology ETF
æ¯ç2.25%
Virtus LifeSci Biotech Clinical Trials ETF
æ¯ç0.99%
ProShares Ultra Nasdaq Biotechnology
æ¯ç0.24%
iShares Micro-Cap ETF
æ¯ç0.18%
Federated Hermes MDT Small Cap Core ETF
æ¯ç0.15%
WisdomTree US SmallCap Quality Growth Fund
æ¯ç0.15%
SPDR S&P International Small Cap ETF
æ¯ç0.14%
Invesco Nasdaq Biotechnology ETF
æ¯ç0.14%
iShares Biotechnology ETF
æ¯ç0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
æ¯ç0.12%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
Zymeworks Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îZymeworks Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
EcoR1 Capital, LLCã¯22.97Mæ ªãä¿æããŠãããããã¯å šäœã®30.56%ã«çžåœããŸãã
Rubric Capital Management LPã¯4.71Mæ ªãä¿æããŠãããããã¯å šäœã®6.27%ã«çžåœããŸãã
BVF Partners L.P.ã¯4.31Mæ ªãä¿æããŠãããããã¯å šäœã®5.73%ã«çžåœããŸãã
Morgan Stanley & Co. LLCã¯3.62Mæ ªãä¿æããŠãããããã¯å šäœã®4.82%ã«çžåœããŸãã
Redmile Group, LLCã¯4.15Mæ ªãä¿æããŠãããããã¯å šäœã®5.52%ã«çžåœããŸãã
EcoR1 Capital, LLCã¯22.97Mæ ªãä¿æããŠãããããã¯å šäœã®30.56%ã«çžåœããŸãã
Rubric Capital Management LPã¯4.71Mæ ªãä¿æããŠãããããã¯å šäœã®6.27%ã«çžåœããŸãã
BVF Partners L.P.ã¯4.31Mæ ªãä¿æããŠãããããã¯å šäœã®5.73%ã«çžåœããŸãã
Morgan Stanley & Co. LLCã¯3.62Mæ ªãä¿æããŠãããããã¯å šäœã®4.82%ã«çžåœããŸãã
Redmile Group, LLCã¯4.15Mæ ªãä¿æããŠãããããã¯å šäœã®5.52%ã«çžåœããŸãã
Zymeworks Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îZymeworks Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
EcoR1 Capital, LLC
Rubric Capital Management LP
BVF Partners L.P.
EcoR1 Capital, LLC
Rubric Capital Management LP
BVF Partners L.P.
Zymeworks IncïŒZYMEïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãZymeworks Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯390瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ74.41Mã§ãå
šäœã®99.43%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯-3.30%å¢å ããŠããŸãã
Zymeworks Incã®æ倧ã®åçæºã¯äœã§ããïŒ
î--ã«ãããŠã--éšéãZymeworks Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
